Company intelligence / Profile preview

Oncocross

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Oncocross has developed AI platforms for drug discovery and development. They have licensed out an AI-developed drug for sarcopenia to Korea Pharma, which was the first licensing deal of an AI-developed drug from an AI biotech to a traditional pharmaceutical company. They are also preparing for Phase 1 clinical trials for an anti-cancer drug originally developed for blood cancer that they identified additional solid cancer indications for using their AI platform.

Therapeutic areas: OncologyRare DiseasesMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

14 assets

OC514

13 more assets in the full pipeline.

Request access →

Partnerships

JW PharmaceuticalKorea Pharma

Beyond the preview

Go deeper on Oncocross.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncocross.

Explore the full profile